LONDON (Alliance News) - The following shares received analyst recommendations Thursday morning and Wednesday:
----------
FTSE 100
----------
BERNSTEIN RAISES GLAXOSMITHKLINE PRICE TARGET TO 1449 (1399) PENCE - 'MARKET-PERFORM'
----------
HSBC RAISES GLAXOSMITHKLINE PRICE TARGET TO 1800 (1700) PENCE - 'BUY'
----------
BARCLAYS RAISES RSA INSURANCE PRICE TARGET TO 434 (425) PENCE - 'EQUAL WEIGHT'
----------
GOLDMAN CUTS BP PRICE TARGET TO 380 (390) PENCE - 'NEUTRAL'
----------
RBC CAPITAL CUTS BP PRICE TARGET TO 370 (390) PENCE - 'SECTOR PERFORM'
----------
TRADERS: MACQUARIE INITIATES LEGAL & GENERAL WITH 'NEUTRAL' - TARGET 189 PENCE
----------
S&P CAPITAL IQ CUTS JOHNSON MATTHEY PRICE TARGET TO 2500 (2800) PENCE
----------
EXANE BNP CUTS JOHNSON MATTHEY PRICE TARGET TO 2500 (2700) PENCE - 'NEUTRAL'
----------
MACQUARIE RAISES INTU PROPERTIES TO 'NEUTRAL' ('UNDERPERFORM') - TP 3,07 PENCE
----------
CITIGROUP CUTS STANDARD CHARTERED PRICE TARGET TO 465 (615) PENCE - 'NEUTRAL'
----------
FTSE 250
----------
GOLDMAN CUTS TALK TALK TELECOM TO 'NEUTRAL' ('BUY') - TARGET 271 (312) PENCE
----------
RBC CAPITAL RAISES TALK TALK TELECOM PRICE TARGET TO 260 (250) P - SECTOR PERFORM
----------
CHARLES STANLEY INITIATES RENISHAW WITH 'HOLD'
----------
MAIN MARKET AND AIM
----------
GOLDMAN CUTS FOXTONS PRICE TARGET TO 223 (227) PENCE - 'NEUTRAL'
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun
Copyright 2016 Alliance News Limited. All Rights Reserved.
Zantac not a cause of woman’s cancer, jury says in first trial over drug
CHICAGO, May 23 (Reuters) - A jury in Chicago on Thursday rejected an Illinois woman’s claim that the now discontinued heartburn drug Zantac caused her colon cancer, in the first trial out of thousands of lawsuits making similar allegations.
Read more